Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in SSc-ILD (SENSCIS)
NCT02597933Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual Rate of Decline in Forced Vital Capacity at 52 weeks. Started Nov 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT02597933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597933.